Bernstein maintained an outperform rating on Paytm with a target price of Rs 600. After >40% decline in the last few days, the stock is once again back at the near doomsday valuations. “We would lean towards the ‘buy now’ camp. We see a healthy upside in our very conservative base case scenario,” said the note.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the